Fengqiang Yu

Dr. Fengqiang Yu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
LZLiangyu Zhang
Liangyu Zhang
XZXun Zhang
Xun Zhang
MGMaohao Guan
Maohao Guan
JZJianshen Zeng
Jianshen Zeng
FYFengqiang Yu
Fengqiang Yu
FLFancai Lai
Fancai Lai

14 May 2024 in Respiratory Research
Verified
Journal Article
Open access
PDF file
LZLiangyu Zhang
Liangyu Zhang
XZXun Zhang
Xun Zhang
MGMaohao Guan
Maohao Guan
JZJianshen Zeng
Jianshen Zeng
FYFengqiang Yu
Fengqiang Yu
FLFancai Lai
Fancai Lai
Background: Previous studies have largely neglected the role of sulfur metabolism in LUAD, and no study has combine iron, copper, and sulfur-metabolism associated genes together to create prognostic signatures. Methods: This study encompasses 1564 LUAD patients, 1249 NSCLC patients, and over 10,000 patients with various cancer types from diverse cohorts. We employed the R package ConsensusClusterPlus to separate patients into different ICSM (Iron, Copper, and Sulfur-Metabolism) subtypes. Various machine-learning methods were utilized to develop the ICSMI. Enrichment analyses were conducted using ClusterProfiler and GSVA, while IOBR quantified immune cell infiltration. GISTIC2.0 and maftools were utilized for CNV and SNV data analysis. The Oncopredict package predicted drug information based on GDSC1. TIDE algorithm and cohorts GSE91061 and IMvigor210 evaluated patient response to immunotherapy. Single-cell data was processed using the Seurat package, AUCell package calculated cells geneset activity scores, and the Scissor algorithm identified ICSMI-associated cells. In vitro experiments was conducted to explore the role of ICSMRGs in LUAD. Results: Unsupervised clustering identified two distinct ICSM subtypes of LUAD, each with unique clinical characteristics. The ICSMI, comprising 10 genes, was constructed using integrated machine-learning methods. Its prognostic power was validated in 10 independent datasets, revealing that LUAD patients with higher ICSMI levels had poorer prognoses. Furthermore, ICSMI demonstrated superior predictive abilities compared to 102 previously published signatures. A nomogram incorporating ICSMI and clinical features exhibited high predictive performance. ICSMI positively correlated with patients gene mutations, and integrated analysis of bulk and single-cell transcriptome data revealed its association with TME modulators. Cells representing the high-ICSMI phenotype exhibited more malignant features. LUAD patients with high ICSMI levels exhibited sensitivity to chemotherapy and targeted therapy but displayed resistance to immunotherapy. In a comprehensive analysis across various cancers, ICSMI retained significant prognostic value and emerged as a risk factor for the majority of cancer patients. Conclusions: ICSMI provides critical prognostic insights for LUAD patients, offering valuable insights into the tumor microenvironment and predicting treatment responsiveness.

28 July 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
LZLiangyu Zhang
Liangyu Zhang
MGMaohao Guan
Maohao Guan
XZXun Zhang
Xun Zhang
FYFengqiang Yu
Fengqiang Yu
FLFancai Lai
Fancai Lai
Background: Innate immune effectors, dendritic cells (DCs), influence cancer prognosis and immunotherapy significantly. As such, dendritic cells are important in killing tumors and influencing tumor microenvironment, whereas their roles in lung adenocarcinoma (LUAD) are largely unknown. Methods: In this study, 1658 LUAD patients from different cohorts were included. In addition, 724 cancer patients who received immunotherapy were also included. To identify DC marker genes in LUAD, we used single-cell RNAsequencing data for analysis and determined 83 genes as DC marker genes. Following that, integrative machine learning procedure was developed to construct a signature for DC marker genes. Results: Using TCGA bulk-RNA sequencing data as the training set, we developed a signature consisting of seven genes and classified patients by their risk status. Another six independent cohorts demonstrated the signature’ s prognostic power, and multivariate analysis demonstrated it was an independent prognostic factor. LUAD patients in the high-risk group displayed more advanced features, discriminatory immune-cell infiltrations and immunosuppressive states. Cell–cell communication analysis indicates that tumor cells with lower risk scores communicate more actively with the tumor microenvironment. Eight independent immunotherapy cohorts revealed that patients with low-risk had better immunotherapy responses. Drug sensitivity analysis indicated that targeted therapy agents exhibited greater sensitivity to low-risk patients, while chemotherapy agents displayed greater sensitivity to high-risk patients. In vitro experiments confirmed that CTSH is a novel protective factor for LUAD. Conclusions: An unique signature based on DC marker genes that is highly predictive of LUAD patients’ prognosis and response to immunotherapy. CTSH is a new biomarker for LUAD.

15 April 2023 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
YZYi Zhuo
Yi Zhuo
XHXuan Huang
Xuan Huang
NLNan-Long Lin
Nan-Long Lin
FYFengqiang Yu
Fengqiang Yu
YCYan-Xun Chen
Yan-Xun Chen
FLFancai Lai
Fancai Lai
The construct of SiO 2 @CaO 2 @DOX@P53–HA and its therapeutical mechanism in cancer cell.

19 October 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
LZLiangyu Zhang
Liangyu Zhang
XZXun Zhang
Xun Zhang
MGMaohao Guan
Maohao Guan
FYFengqiang Yu
Fengqiang Yu
FLFancai Lai
Fancai Lai
Background: Cell death caused by neutrophil extracellular traps (NETs) is known as NETosis. Despite the increasing importance of NETosis in cancer diagnosis and treatment, its role in Non-Small-Cell Lung Cancer (NSCLC) remains unclear.Methods: A total of 3298 NSCLC patients from different cohorts were included. The AUCell method was used to compute cells’ NETosis scores from single-cell RNA-sequencing data. DEGs in sc-RNA dataset were obtained by the Seurat’s “FindAllMarkers” function, and DEGs in bulk-RNA dataset were acquired by the DESeq2 package. ConsensusClusterPlus package was used to group patients into different NETosis subtypes, and the Enet algorithm was used to construct the NETosis-Related Riskscore (NETRS). Enrichment analyses were conducted using the GSVA and ClusterProfiler packages. Six distinct algorithms were utilized to evaluate patients’ immune cell infiltration level. Patients’ SNV and CNV data were analyzed by maftools and GISTIC2.0, respectively. Drug information was obtained from the GDSC1, and predicted by the Oncopredict package. Patient response to immunotherapy was evaluated by the TIDE algorithm in conjunction with the phs000452 immunotherapy cohort. Six NRGs’ differential expression was verified using qRT-PCR and immunohistochemistry.Results: Among all cell types, neutrophils had the highest AUCell score. By Intersecting the DEGs between high and low NETosis classes, DEGs between normal and LUAD tissues, and prognostic related genes, 61 prognostic related NRGs were identified. Based on the 61 NRGs, all LUAD patients can be divided into two clusters, showing different prognostic and TME characteristics. Enet regression identified the NETRS composed of 18 NRGs. NETRS significantly associated with LUAD patients’ clinical characteristics, and patients at different NETRS groups showed significant differences on prognosis, TME characteristics, immune-related molecules’ expression levels, gene mutation frequencies, response to immunotherapy, and drug sensitivity. Besides, NETRS was more powerful than 20 published gene signatures in predicting LUAD patients’ survival. Nine independent cohorts confirmed that NETRS is also valuable in predicting the prognosis of all NSCLC patients. Finally, six NRGs’ expression was confirmed using three independent datasets, qRT-PCR and immunohistochemistry.Conclusion: NETRS can serves as a valuable prognostic indicator for patients with NSCLC, providing insights into the tumor microenvironment and predicting the response to cancer therapy.

25 February 2024 in Biotechnology Journal
Verified
Journal Article
Closed access
FYFengqiang Yu
Fengqiang Yu
YCYanxun Chen
Yanxun Chen
WYWeiqiang Yi
Weiqiang Yi
MGMaohao Guan
Maohao Guan
NLNanlong Lin
Nanlong Lin
FLFancai Lai
Fancai Lai